CellBank

What CellBank does

CellBank Corp. (株式会社セルバンク) is a privately held Japanese regenerative medicine company founded in 2004 and headquartered in Tokyo. The company operates a GMP-compliant Cell Processing Center (CPC) with independent air conditioning and bioclane rooms, specializing in the manufacturing, cryopreservation, and distribution of two core cell products: cultured dermal fibroblasts (真皮線維芽細胞) for skin regeneration therapy, and adipose-derived mesenchymal stem cells (脂肪由来幹細胞) for knee osteoarthritis and breast regeneration applications. Its proprietary technology platform centers on 100% self-serum cell culture (eliminating animal-derived FBS), strict cell passage limits (max 5 for dermal fibroblasts, max 3 for ASC), high-volume batch production of over 600 million cells per batch, and semi-permanent liquid nitrogen cryopreservation at approximately -196°C with VNTR-based individual identification for sample integrity.

The company operates a B2B2C business model. CellBank sells processed cells directly to medical institutions — dermatology, orthopedic, cosmetic surgery, and pain clinics across Japan — at industry-lowest unit pricing of 25,000-35,000 yen per 10 million cells. Beyond cell supply, it provides turnkey adoption support including regulatory application consulting, ethics committee introduction, staff training, and 24/7 partner clinic support, enabling clinics to begin offering regenerative medicine treatments in as little as two months. A secondary subscription-based revenue stream derives from individual cell banking services, where patients cryopreserve their own cells for future therapeutic use. The company also drives consumer demand through an extensive content ecosystem including founder-led YouTube channels, podcasts, a beauty knowledge blog, and social media, channeling patient referrals to its partner clinic network. Since founding, CellBank reports supporting over 30,000 treatments across its clinic network.

Name

CellBank

Legal name

株式会社セルバンク

Website

https://cellbank.co.jp

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

CellBank Corp. is a Japanese regenerative medicine company that manufactures and cryopreserves autologous dermal fibroblasts and adipose-derived stem cells, supplying them to medical institutions across Japan for skin regeneration, knee osteoarthritis, and breast treatments, with over 30,000 cumulative treatments supported since 2004.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Cell Processing Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Health Services (8000)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industries

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine services
• Cell processing manufacturing
• Cryopreservation services
• Stem cell therapy
• Cell banking storage

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Cell processing and manufacturing (特定細胞加工物製造事業): CellBank manufactures and provides processed cells (dermal fibroblasts and adipose-derived stem cells) to partner medical institutions. Pricing is per batch of 10 million cells. This is the core B2B revenue stream supporting regenerative medicine treatments at clinics.
2. Cell banking service (細胞保管事業): Provides semi-permanent cryopreservation services for patients' own cells (skin cells). Patients can store their young, healthy cells for future use in regenerative treatments, creating a long-term recurring relationship.
3. Regenerative medicine support services (再生医療支援事業): Comprehensive support services for medical institutions adopting regenerative medicine, including application consulting, committee introduction, staff training, and ongoing operational support.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Core offering

CellBank manufactures and supplies cultured autologous cells — dermal fibroblasts (真皮線維芽細胞) and adipose-derived mesenchymal stem cells (脂肪由来幹細胞) — to medical institutions across Japan for use in skin regeneration, knee osteoarthritis, and breast regenerative medicine treatments. The company also provides long-term cryopreservation (cell banking) services for individual patients and end-to-end regenerative medicine implementation support for clinics, including licensing consulting, ethics committee introduction, staff training, and 24/7 operational support.

Differentiator

Problem solved

Functional benefit

Products and services

• Specific Cell Processing Product Manufacturing Business (特定細胞加工物製造事業) Manufacture and supply of processed autologous cells — cultured dermal fibroblasts (真皮線維芽細胞) and adipose-derived mesenchymal stem cells (脂肪由来幹細胞) — sold per batch of 10 million cells to partner medical institutions for use in skin regeneration, knee osteoarthritis, and breast regenerative medicine treatments.
• Cell Banking Service (細胞保管事業) Semi-permanent cryopreservation of patients' own cells (primarily skin cells) in liquid nitrogen at approximately -196°C, allowing health-conscious individuals to preserve young, healthy cells for potential future anti-aging and regenerative medicine treatments; operates as a recurring subscription service.
• Regenerative Medicine Implementation Support (再生医療支援事業) Comprehensive consulting and operational support for medical institutions adopting regenerative medicine, covering licensing application consulting, regenerative medicine committee introduction, staff training, cell manufacturing, transport, ongoing operations, and a 24/7 partner support center; the adoption process can be completed in as little as two months.

Quantifiable outcome

• 30,000+ treatments completed using CellBank cells
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• 膝の痛み専門 大阪梅田セルクリニック (Osaka Umeda Cell Clinic)coreChannel Partner/ Reseller/ DistributorDr. Yasuda Shingo leads this knee pain specialist clinic in Osaka Umeda. The clinic provides knee osteoarthritis regenerative medicine treatments using CellBank's adipose-derived stem cells. They have collaborated on treatment seminars and educational content.
• 松本クリニック (Matsumoto Clinic)coreChannel Partner/ Reseller/ DistributorPartner clinic providing knee osteoarthritis regenerative medicine treatments using CellBank's stem cells.
• 日本ウェルネス再生クリニック (Japan Wellness Regenerative Clinic)coreChannel Partner/ Reseller/ DistributorFormerly Wellness Beauty Clinic Osaka. Multi-specialist clinic offering safe, minimally invasive knee treatments for elderly patients using CellBank cells. Located in Osaka.
• 提携医療機関ネットワーク (Partner medical institution network)coreChannel Partner/ Reseller/ DistributorCellBank works with a nationwide network of medical institutions across Japan that provide regenerative medicine treatments using the company's cells. Patients can search for treatment-available clinics by region and treatment type on CellBank's website.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Catalent Cell Therapy Services: Major global CDMO providing cell therapy manufacturing, fill-finish, and process development services. Comparable in cell therapy manufacturing capabilities and clinical/commercial supply chain role, though focused on broader cell types and larger markets.
• Lonza Cell & Gene Therapies: Global CDMO leader providing cell therapy manufacturing services (autologous and allogeneic). Comparable in cell therapy manufacturing services infrastructure, quality systems, and regulatory compliance — though operating at much larger global scale.
• FUJIFILM Cellular Dynamics (FCDI): Global iPSC-derived cell manufacturing arm of FUJIFILM (which also owns J-TEC). Comparable in cell manufacturing services infrastructure and clinical-grade cell production, though focused on iPSC versus CellBank's autologous MSC/fibroblast focus.
• ROHTO Pharmaceutical (Regenerative Medicine Division): Large Japanese pharmaceutical company with regenerative medicine activities including cell processing for cosmetic and therapeutic applications. Broader pharmaceutical portfolio but overlapping in autologous cell products and skincare-focused regenerative medicine.

Direct peers

• StemCell Institute Inc. Japanese cell bank and regenerative medicine provider offering stem cell banking and storage services. Comparable in cell preservation/banking and treatment support offerings to CellBank's storage business.
• Cyto Potal, Inc. Japanese cell banking and storage company offering personal cell preservation services. Directly comparable to CellBank's cell banking subscription business for individual customers preserving autologous cells.
• Japan Tissue Engineering Co., Ltd. (J-TEC): Japan's leading regenerative medicine company, now a FUJIFILM subsidiary. Develops and supplies autologous cultured cell products (including autologous cultured epidermis and cartilage) — directly comparable in autologous cell manufacturing and clinical application focus to CellBank.
• Twocells Co., Ltd. Japanese regenerative medicine company providing stem cell processing services and treatment network support, with operations in cell culture, cryopreservation, and clinic partner enablement — closely mirrors CellBank's end-to-end service model.
• MEDINET Co., Ltd. Tokyo-based cell therapy services company providing cell processing, contract manufacturing, and cell banking for regenerative medicine applications. Directly competes with CellBank in Japanese cell processing CDMO and storage services.

Emerging players

• CellSeed Inc. Japanese regenerative medicine company focused on epithelial cell sheet engineering. Operates in adjacent autologous cell technology space for epithelial regeneration, comparable in regulatory pathway and clinical application focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/hadasaibou
• YouTubeyoutube.com/@cellbank-TV
• Facebookfacebook.com/Cellbank
• Instagraminstagram.com/cellbank_official

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellBank